Insmed
INSM
101 hedge funds and large institutions have $765M invested in Insmed in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 12 closing their positions.
93.41% more ownership
Funds ownership: 0% → 93.41% (+93%)
62% more call options, than puts
Call options by funds: $5.5M | Put options by funds: $3.4M
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
2% more funds holding
Funds holding: 99 → 101 (+2)
8% less capital invested
Capital invested by funds: $834M → $765M (-$69.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$6.24M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$4.85M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$4.63M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.58M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$8.62M |
| 3 |
Millennium Management
New York
|
-$7.62M |
| 4 |
Asset Management One
Tokyo,
Japan
|
-$3.71M |
| 5 |
Goldman Sachs
New York
|
-$3.23M |
INSM Hedge Fund Activity: Q4 2016 in Review
101 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q4 2016, worth a combined $765M — down 8.3% from $834M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new INSM positions and 12 closed out — a net gain of 3 holders — while 37 added to existing stakes and 26 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $6.4M. The largest seller was Citadel Advisors, cutting an estimated $9.58M.
- 101 institutional investors held Insmed (INSM) as of Q4 2016, up from 99 in Q3 2016.
- Funds reported $765M of Insmed stock for Q4 2016, down 8.3% quarter-over-quarter.
- 15 funds opened new Insmed positions in Q4 2016 and 12 closed out, a net change of +3 holders.
- The largest Insmed buyer in Q4 2016 was T. Rowe Price Associates, an estimated $6.4M added.
- The largest Insmed seller in Q4 2016 was Citadel Advisors, an estimated $9.58M sold.
Based on aggregated 13F filings for Q4 2016.